Related Experiment Video
Updated: Jun 29, 2026
A Preclinical Controlled Cortical Impact Model for Traumatic Hemorrhage Contusion and Neuroinflammation
Published on: June 10, 2020
Neuroprotection in traumatic brain injury
1Jain PharmaBiotech, Blaesiring 7, CH-4057 Basel, Switzerland. jain@pharmabiotech.ch
Abstract:
The management of traumatic brain injury (TBI) is challenging and there is a need for neuroprotective therapies. A better understanding of the pathomechanism of TBI, particularly of the evolution of secondary damage, is providing targets for new approaches and selected ones in clinical development are described. Clinical trials that have been discontinued in the past for lack of efficacy or other reasons are also listed. One of the problems has been the translation of promising animal experimental results into clinically successful therapies. The complexity of sequelae of TBI requires a multifaceted approach. In addition to the investigation of drugs for neuroprotective effect in TBI, new technologies based on cell/gene therapies, biomarkers and nanobiotechnology are being employed for the integration of neuroprotection with neuroregeneration and are promising.
Insights
Developing effective treatments for traumatic brain injury (TBI) is crucial. Current research focuses on understanding TBI
Area of Science:
- Neuroscience
- Neurology
- Biomedical Engineering
Background:
- Traumatic brain injury (TBI) management presents significant challenges, highlighting the urgent need for effective neuroprotective therapies.
- Understanding the intricate pathomechanisms of TBI, especially the progression of secondary damage, is key to identifying novel therapeutic targets.
Purpose of the Study:
- To review current and emerging therapeutic strategies for TBI.
- To discuss challenges in translating preclinical findings to clinical success.
- To explore innovative approaches integrating neuroprotection and neuroregeneration.
Main Methods:
- Review of clinical trial data, including discontinued studies.
- Analysis of emerging technologies such as cell/gene therapy, biomarkers, and nanobiotechnology.
- Examination of the pathomechanism of secondary injury in TBI.
Main Results:
- Several neuroprotective therapies are in clinical development for TBI.
- Past clinical trials have faced challenges with efficacy and translation from animal models.
- New technologies offer promise for combined neuroprotection and neuroregeneration.
Conclusions:
- A multifaceted approach is required to address the complex sequelae of TBI.
- Integrating neuroprotection with neuroregeneration using advanced technologies holds significant promise for future TBI management.
- Continued research into TBI pathomechanisms and therapeutic interventions is essential.
Related Concept Videos
01:28Traumatic Brain Injury l: Introduction
01:15Neurogenesis and Regeneration of Nervous Tissue
00:49The Blood-brain Barrier